证券代码：300357 证券简称：我武生物 编号：2022-004 浙江我武生物科技股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | |-------------------------|-----------------------------------------------|---------------------------------------------------------------------------------------------------------|--------------------------------------| | 投资者关系活 \n动类别 | □ 特定对象调研 \n□ 业绩说明会 □ \n□ 现场参观 | □ 分析师会议 □ \n新闻发布会 □ \n■ 其他（分析师电话会议） | 媒体采访 \n路演活动 | | 参与单位名称 及人员姓名 | 共 51 家机构 61 | 名人员参加，详见附件 | | | 时间 | 2022 年 08 月 26 日 | 10:00-11:00 | | | 地点 | 电话会议 | | | ...

证券代码：300357 证券简称：我武生物 编号：2022-006 1 浙江我武生物科技股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | |-----------------------|--------------------------------------------|-------------------------------------------------------------------------------------------|-------------------------------------------------| | 投资者关系活 \n动类别 | ■ 特定对象调研 \n□ 业绩说明会 \n□ 现场参观 | □ 分析师会议 □ \n □ 新闻发布会 □ \n □ 其他 | 媒体采访 \n路演活动 | | 参与单位名称 | 华泰资管 | 李勇剑；富国基金 娄圣睿；淡水泉投资 | 王沛；肇万 | | 及人员姓名 | 资产 阮帅、粟琳、石明杰 | 李大瑞；兴业基金 高观朋；浙商基金 | 黄文敏；信达证券 | | 时间 | 2022 年 1 ...

证券代码：300357 证券简称：我武生物 编号：2022-005 浙江我武生物科技股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | |-------------------------|-----------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------|--------------------------| | 投资者关系活 \n动类别 | □ 特定对象调研 \n□ 业绩说明会 □ \n□ 现场参观 | □ 分析师会议 □ \n新闻发布会 □ \n■ 其他（分析师电话会议） | 媒体采访 \n路演活动 | | 参与单位名称 及人员姓名 | 共 94 家机构 117 | 名人员参加，详见附件。 | | | 时间 | 2022 年 10 月 26 日 | 10:00-11:00 ；下午 15 ...

Financial Performance - The company's revenue for Q3 2022 reached ¥311,276,362.24, representing a year-over-year increase of 14.39%[6] - Net profit attributable to shareholders was ¥146,134,890.04, up 14.82% compared to the same period last year[6] - The net profit excluding non-recurring gains and losses was ¥139,042,241.87, reflecting a 10.71% increase year-over-year[6] - Total operating revenue for the period reached CNY 700,180,586.99, an increase of 12.97% compared to CNY 619,721,426.61 in the previous period[25] - Operating profit amounted to CNY 376,374,455.50, up from CNY 318,961,574.10, reflecting a growth of 17.94%[28] - Net profit attributable to shareholders of the parent company was CNY 327,216,170.63, compared to CNY 274,592,849.47, representing a year-on-year increase of 19.09%[30] - The total comprehensive income for the period was CNY 318,947,061.08, compared to CNY 266,291,359.95, reflecting a growth of 19.77%[30] Cash Flow - Cash flow from operating activities for the year-to-date period was ¥250,043,126.59, showing a 3.30% increase[6] - Operating cash flow for the period was CNY 250,043,126.59, an increase from CNY 242,046,010.16 in the previous period, reflecting a growth of approximately 3.3%[32] - Cash inflow from operating activities totaled CNY 717,199,650.55, compared to CNY 597,623,360.81 in the prior period, indicating an increase of about 20%[32] - Cash outflow from operating activities was CNY 467,156,523.96, up from CNY 355,577,350.65, representing a rise of approximately 31.3%[32] - Net cash flow from investment activities was CNY 30,898,065.63, a significant improvement from a net outflow of CNY 156,597,122.56 in the previous period[35] - Cash inflow from investment activities amounted to CNY 585,555,974.38, slightly up from CNY 578,541,929.36 year-over-year[35] - Cash outflow from investment activities decreased to CNY 554,657,908.75 from CNY 735,139,051.92, showing a reduction of about 24.5%[35] - Net cash flow from financing activities was CNY -108,292,366.40, worsening from CNY -89,862,925.67 in the previous period[35] - The ending cash and cash equivalents balance was CNY 452,384,667.95, up from CNY 216,616,892.70, indicating a significant increase of approximately 108.8%[35] Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥2,146,643,321.82, an increase of 11.11% from the end of the previous year[6] - The company's equity attributable to shareholders increased to ¥1,958,073,388.87, up 12.79% from the previous year[6] - The total assets of the company reached RMB 2.15 billion, compared to RMB 1.93 billion at the beginning of the year, reflecting an increase of about 11.2%[20] - The company's total current liabilities decreased to RMB 98.38 million from RMB 107.99 million, a reduction of approximately 8.5%[20] - The non-current assets totaled RMB 696.27 million, up from RMB 590.45 million, marking an increase of about 18%[20] - The company's total liabilities stood at CNY 136,332,083.79, slightly up from CNY 135,356,468.28, reflecting a marginal increase of 0.72%[24] Shareholder Information - The total number of common shareholders at the end of the reporting period is 20,309[15] - The largest shareholder, Zhejiang Wawu Management Consulting Co., Ltd., holds 38.86% of shares, totaling 203,454,131 shares[15] - The company has no preferred shareholders as of the reporting period[15] Other Income and Expenses - Other income for the year-to-date period increased by ¥18,926,837.07, a growth of 171.22%, mainly from government subsidies[12] - Other income for the period was CNY 29,981,000.25, significantly higher than CNY 11,054,163.18 from the previous period, representing an increase of 171.56%[25] - Research and development expenses increased to CNY 76,318,393.79, up from CNY 60,905,616.89, marking a rise of 25.16%[25] - Employee compensation payments rose to CNY 209,137,185.70 from CNY 170,589,965.13, reflecting an increase of approximately 22.5%[32] Inventory and Accounts Receivable - Accounts receivable increased by ¥72,878,728.29, a rise of 46.68%, primarily due to increased revenue[11] - Accounts receivable rose to RMB 228.99 million, up from RMB 156.11 million, indicating a year-on-year increase of approximately 46.3%[18] - The company reported a significant increase in inventory, which decreased to RMB 47.29 million from RMB 53.75 million, a decline of approximately 12.1%[18] Product Development and Market Strategy - The company has not disclosed any new product developments or market expansion strategies in the current report[15]

Product Performance - The company's main product, "Dust Mite Drops," accounted for a significant portion of revenue, indicating a high dependency on this product for profitability [9]. - The sales revenue from "Dust Mite Drops" was ¥381,971,977.10, while "Artemisia Pollen Allergen Sublingual Drops" generated ¥3,857,419.02 in sales [64]. - The "Dust Mite Drops" is used for desensitization treatment of allergic rhinitis and asthma, classified as a Category 4 therapeutic biological product [68]. - The "dust mite drops" are used for desensitization therapy for allergic rhinitis and asthma caused by dust mites, with optimal survival conditions for dust mites being 20℃-30℃ and 70%-80% humidity [59]. - The company has launched a new product, "Artemisia pollen sublingual drops," which complements its existing "dust mite drops" for allergen desensitization treatment, targeting different allergic conditions in various regions [59]. Financial Performance - The company reported a high gross profit margin, but potential fluctuations in drug prices and costs could impact future profitability [9]. - The company's operating revenue for the reporting period was ¥388,904,224.75, an increase of 11.88% compared to ¥347,604,830.93 in the same period last year [34]. - The net profit attributable to shareholders was ¥181,081,280.59, reflecting a growth of 22.92% from ¥147,316,566.21 year-on-year [34]. - The net profit after deducting non-recurring gains and losses was ¥154,035,008.92, up 15.98% from ¥132,813,880.84 in the previous year [34]. - The net cash flow from operating activities was ¥166,039,082.05, representing a 17.33% increase from ¥141,509,362.09 in the same period last year [34]. - Basic earnings per share rose to ¥0.3458, a 22.89% increase compared to ¥0.2814 in the previous year [34]. - Total assets at the end of the reporting period were ¥1,979,305,678.90, up 2.45% from ¥1,931,961,023.89 at the end of the previous year [34]. - The net assets attributable to shareholders increased by 4.37% to ¥1,811,921,679.68 from ¥1,736,067,935.33 at the end of the last year [34]. Research and Development - The company is actively developing new products in the field of allergic diseases, with multiple projects achieving significant progress [69]. - The company has established a dedicated R&D team with a research center and three related departments, focusing on the development of biopharmaceuticals [62]. - The company is expanding its product line with several R&D projects, including the "Artemisia Pollen Allergen Sublingual Drops" which is currently in the CDE technical review stage [69]. - The company has developed a self-sufficient stem cell culture system and a series of core technologies, enhancing its capabilities in stem cell research and development [51]. - The company is actively expanding into the natural medicine sector, focusing on discovering new structures and molecules to combat antibiotic-resistant bacteria [52]. Market and Industry Trends - The biopharmaceutical industry in China is experiencing rapid growth, driven by increasing healthcare spending and an aging population [45]. - Recent regulatory changes in China's pharmaceutical sector aim to enhance quality management and encourage innovation in drug development [46]. - The regulatory environment for the biopharmaceutical industry is becoming increasingly stringent, with higher quality management standards and entry barriers [48]. - The market for desensitization therapy is expanding, with increasing clinical acceptance of sublingual immunotherapy for allergic rhinitis [64]. - The company emphasizes the importance of seasonal sales patterns, particularly in the summer and autumn when dust mites proliferate, leading to increased allergic disease cases [52]. Risk Management - The company is facing risks related to industry policy changes, which may affect production and operational stability [9]. - The company acknowledges the lengthy drug development process due to regulatory requirements, which may delay market entry for new products [13]. - The company is actively monitoring industry policy changes and will implement measures to mitigate associated risks [9]. - The company faces risks from tightening industry regulations and will actively monitor policy changes to mitigate operational risks [113]. - The company is addressing the risk of price reductions in drug tenders by potentially increasing supply through pharmacy channels [114]. Corporate Governance and Social Responsibility - The company will not distribute cash dividends or issue bonus shares, focusing on reinvestment for growth [13]. - The company has a 100% participation rate in employee social insurance and housing fund programs, ensuring employee rights and benefits [144]. - The company has implemented a comprehensive safety management system, conducting regular safety training and inspections to ensure workplace safety [146]. - The company actively fulfills social responsibilities, providing pandemic relief packages to employees during the Shanghai lockdown [153]. - The company promotes green office practices, advocating for paperless operations to enhance environmental awareness among employees [148]. Environmental Compliance - The company has implemented strict environmental protection measures, including the addition of 1 new waste gas treatment device and 3 combustible gas detectors during the reporting period [128]. - The company received approval for the environmental impact report of its stem cell research phase II project from the Shanghai Xuhui District Ecological Environment Bureau in March 2022 [129]. - The company has established an emergency response plan for environmental incidents, identifying risks and forming a specialized response team [130]. - The company conducted monthly air quality tests and quarterly wastewater and noise assessments in accordance with its self-monitoring plan [131]. - The company achieved energy management system certification in July 2022, promoting energy efficiency and reducing carbon emissions [135]. Shareholder Information - The company’s controlling shareholder is Wo Wu Consulting, with Hu Gengxi and Yanni Chen as actual controllers [196]. - The number of ordinary shareholders at the end of the reporting period was 22,324 [193]. - The company’s major shareholder, Wo Wu Consulting, holds 38.86% of the shares, totaling 203,454,131 shares [193]. - The total number of shares held by the top 10 shareholders indicates a concentrated ownership structure [200]. - The data reflects a stable shareholder base with no significant changes in the top holdings during the reporting period [200].

Financial Performance - The company's revenue for Q1 2022 was CNY 197,587,530.67, representing a 20.00% increase compared to CNY 164,654,385.39 in the same period last year[3]. - Net profit attributable to shareholders for Q1 2022 was CNY 91,735,430.39, a 30.21% increase from CNY 70,454,208.66 year-on-year[3]. - The net profit after deducting non-recurring gains and losses was CNY 76,730,047.57, up 27.68% from CNY 60,097,081.22 in the previous year[3]. - Basic earnings per share for Q1 2022 were CNY 0.1752, reflecting a 30.16% increase from CNY 0.1346 in the previous year[3]. - The net profit for the current period is 88,969,235.15, compared to 67,726,952.32 in the previous period, representing an increase of approximately 31.2%[28]. - The total profit for the current period is 106,121,775.74, up from 80,882,386.26 in the previous period, indicating a growth of about 31.2%[28]. - The operating profit for the current period is 104,953,424.10, compared to 80,960,799.18 in the previous period, reflecting an increase of approximately 29.6%[28]. - The total comprehensive income attributable to the parent company's owners is 91,733,178.17, compared to 70,455,445.49 in the previous period, representing an increase of about 30.2%[30]. Cash Flow and Assets - The net cash flow from operating activities decreased by 44.38% to CNY 55,592,478.71, down from CNY 99,954,766.48 in the same period last year[3]. - The cash flow from operating activities for the current period is 55,592,478.71, down from 99,954,766.48 in the previous period, a decrease of approximately 44.2%[35]. - The cash and cash equivalents at the end of the period amount to 298,128,769.36, down from 376,413,028.97 in the previous period, a decrease of approximately 20.7%[38]. - The net cash flow from investing activities is -36,137,641.70, compared to 56,741,590.98 in the previous period, indicating a decline in cash flow from investments[35]. - The total operating cash inflow for the current period is 229,210,561.85, compared to 208,110,123.73 in the previous period, an increase of about 10.1%[32]. - The total operating cash outflow for the current period is 173,618,083.14, compared to 108,155,357.25 in the previous period, an increase of approximately 60.5%[35]. - As of March 31, 2022, the cash and cash equivalents amount to 722,401,521.65 RMB, an increase from 649,994,339.83 RMB at the beginning of the year[15]. - The company's total assets at the end of the reporting period were CNY 1,972,265,388.56, a 2.09% increase from CNY 1,931,961,023.89 at the end of the previous year[3]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 26,044[9]. - Zhejiang Wawu Management Consulting Co., Ltd. holds 38.86% of shares, totaling 203,454,131 shares[9]. - Hu Gengxi holds 10.34% of shares, totaling 54,150,370 shares, with 40,612,777 shares pledged[9]. - The company has a total of 52,552,708 restricted shares, with 40,612,777 shares released from restrictions for Hu Gengxi[13]. - The company has not disclosed any related party relationships among the top ten shareholders[12]. - The company has a total of 4.01% of shares held by the National Social Security Fund, totaling 20,992,738 shares[9]. Research and Development - R&D expenses increased by 33.25% to CNY 6,699,422.29, reflecting the company's increased investment in research and development[6]. - Research and development expenses for the current period were ¥26,850,068.69, compared to ¥20,150,646.40 in the previous period, reflecting a rise of approximately 33.16%[25]. - The company completed Phase III clinical trials for "Artemisia Annua Pollen Allergen Sublingual Drops" for children with rhinitis[14]. - The company has received acceptance notifications for multiple drug applications, including "Liu Cao Pollen Puncture Liquid" and "Artemisia Annua Pollen Allergen Sublingual Drops" in January 2022[14]. Operating Costs - Total operating costs amounted to ¥108,106,533.70, up from ¥95,287,072.98, indicating an increase of about 13.91%[25]. - The company's total liabilities decreased to ¥86,693,850.02 from ¥135,356,468.28, a reduction of approximately 35.94%[21]. - The total equity attributable to shareholders of the parent company increased to ¥1,827,801,113.50 from ¥1,736,067,935.33, marking a growth of about 5.27%[24]. - The company's stock issuance approval from the China Securities Regulatory Commission has automatically expired[14]. - The company’s contract liabilities increased to ¥658,795.28 from ¥417,459.94, reflecting a growth of approximately 57.73%[21].

Product Performance and Development - The company's main product, "Dust Mite Drops," accounted for a significant portion of revenue, indicating a high dependency on this product for profitability[11] - The new product "Artemisia Flower Pollen Allergen Sublingual Drops" received regulatory approval on January 30, 2021, but large-scale sales will take time to develop[11] - The company has launched several products, including the Dust Mite Drops and the Mugwort Pollen Sublingual Drops, with the latter receiving regulatory approval on January 30, 2021[59] - The Dust Mite Drops are specifically used for desensitization treatment of allergic rhinitis and asthma caused by dust mite allergies, with various concentrations available[59] - The new Mugwort Pollen Sublingual Drops complement the existing Dust Mite Drops, providing additional treatment options for patients with different allergies[62] - The company is actively expanding its product line with new products in various stages of clinical trials, including sublingual drops for pollen allergies and dust mite allergy treatments[65][69] - The company is advancing clinical trials for various allergen products, including the III phase clinical trial for the "Pollen Stabbing Liquid" and I phase trials for dermatitis diagnostic patches[146] Financial Performance - The company's operating revenue for 2021 was CNY 807,691,606, representing a 26.95% increase compared to CNY 636,208,242.62 in 2020[33] - The net profit attributable to shareholders for 2021 was CNY 337,991,284.82, up 21.38% from CNY 278,447,284.42 in 2020[33] - The net profit after deducting non-recurring gains and losses was CNY 315,817,153.17, reflecting a 20.78% increase from CNY 261,472,997.24 in 2020[33] - The net cash flow from operating activities reached CNY 360,575,120.69, a 40.73% increase compared to CNY 256,221,705.88 in 2020[33] - The total assets at the end of 2021 were CNY 1,931,961,023.89, a 20.39% increase from CNY 1,604,755,527.30 at the end of 2020[33] - The basic earnings per share for 2021 was CNY 0.6455, up 21.38% from CNY 0.5318 in 2020[33] - The weighted average return on equity for 2021 was 21.45%, an increase of 0.90% from 20.55% in 2020[33] Research and Development - The company is committed to continuous R&D innovation, particularly in the fields of stem cells, natural medicines, and medical artificial intelligence[57] - R&D investment totaled CNY 102,025,193, accounting for 12.63% of operating revenue, with CNY 50,572,962.30 allocated to stem cell research and CNY 10,754,442.66 to natural medicine[74] - The company has over 200 R&D personnel, ensuring a strong talent reserve for innovation and development[73] - The company’s research and development efforts are supported by national policies, enhancing the prospects for new drug development in the stem cell field[55] - The company completed Phase I clinical trials for its inhaled product, indicating progress in its product pipeline[106] Market and Competitive Position - The biopharmaceutical industry in China is experiencing rapid growth, driven by increasing healthcare spending and an aging population[50] - The company maintains a leading position in the sublingual desensitization treatment market, with only its products approved for sale in China[54] - The company has benefited from the tightening of industry regulations, which raises the entry barriers for competitors[51] - The market for desensitization therapy is expanding, with increasing clinical acceptance of sublingual immunotherapy for allergic rhinitis[64] - The company is entering high-potential markets such as stem cell therapy, natural medicines, and medical artificial intelligence, aiming to form new product clusters in 2-3 pharmaceutical fields over the next decade[146] Risk Management - The company faces risks related to industry policy changes, including stricter regulations and price reductions due to healthcare cost controls[9] - The management team is focused on closely monitoring industry policy changes to adapt strategies accordingly[9] - The company acknowledges the risk of price reductions in drug tenders, which could impact performance, and is considering alternative sales channels to stabilize prices[149] - The company is committed to strict compliance with drug registration regulations, which may prolong the development timeline for new drugs[149] Corporate Governance - The company has established a robust corporate governance structure, including a board of directors and various committees, to enhance operational efficiency[154] - The company actively respects and protects the rights of stakeholders, promoting balanced interests among shareholders, employees, and society[163] - The company maintains independent operations in business, personnel, assets, institutions, and finance, ensuring no reliance on the controlling shareholder[164][165][166][167][168] - The company has a diverse board with members holding various academic and professional backgrounds, including PhDs and master's degrees in relevant fields[180][181][182] Shareholder and Management Information - The total pre-tax remuneration for directors, supervisors, and senior management was 634.1 million CNY[192] - The remuneration for the chairman and general manager, Hu Gengxi, was 78 million CNY[192] - The financial director, Wang Guoqi, received a remuneration of 104 million CNY[192] - The company has no penalties from securities regulatory agencies for directors, supervisors, and senior management in the past three years[189] - The company reported a total of 62,530,370 shares held by board members at the end of the reporting period, with a net decrease of 135,217 shares due to personal financial needs of a director[176]

Financial Performance - The company's revenue for Q3 2021 reached ¥272,116,595.68, representing a year-over-year increase of 17.48%[5] - Net profit attributable to shareholders was ¥127,276,283.26, up 4.26% compared to the same period last year[5] - The net profit after deducting non-recurring gains and losses was ¥125,588,217.73, reflecting a 10.17% increase year-over-year[5] - Total operating revenue for the current period reached ¥619,721,426.61, an increase of 26.2% compared to ¥491,058,886.79 in the previous period[30] - Net profit for the current period was ¥266,294,363.50, representing a 19.2% increase from ¥223,376,917.75 in the previous period[33] - The company reported a total profit of ¥320,968,916.49, which is a 20.6% increase from ¥265,996,849.31 in the previous period[33] - Basic earnings per share for the current period were ¥0.5244, compared to ¥0.4376 in the previous period, reflecting a growth of 19.8%[37] Cash Flow - Cash flow from operating activities amounted to ¥242,046,010.16, showing a 26.51% increase from the beginning of the year[5] - Cash flow from operating activities generated ¥564,509,773.24, an increase from ¥457,394,693.03 in the previous period[38] - Operating cash inflow totaled CNY 597,623,360.81, an increase of 22.4% compared to CNY 488,077,643.62 in the previous period[41] - Cash outflow from operating activities was CNY 355,577,350.65, up from CNY 296,750,411.43, resulting in a net cash flow from operating activities of CNY 242,046,010.16, an increase of 26.5%[41] - Cash inflow from investment activities reached CNY 578,541,929.36, compared to CNY 309,978,793.06, marking an increase of 86.6%[41] - Cash outflow from investment activities was CNY 735,139,051.92, significantly higher than CNY 365,238,079.30, leading to a net cash flow from investment activities of CNY -156,597,122.56[41] - Cash flow from financing activities resulted in a net outflow of CNY -89,862,925.67, compared to CNY -94,245,120.00 in the previous period[44] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,853,615,234.67, a 15.51% increase from the previous year[7] - The company's equity attributable to shareholders increased to ¥1,666,004,937.21, marking a 14.43% rise year-over-year[7] - The total liabilities of the company as of September 30, 2021, were RMB 89,793,384.44, compared to RMB 55,419,690.55 in the previous year[25] - Total liabilities reached ¥123,669,634.97, an increase of 61.5% from ¥76,607,698.67 in the previous period[29] - The total current liabilities were 55,419,690.55, reflecting a decrease from 60,881,547.98[51] - The non-current liabilities totaled 21,188,008.12, down from 25,905,218.01[51] Investments and Expenses - Research and development expenses rose by ¥16,414,616.51, an increase of 36.89%, driven by ongoing investments in existing projects[9] - Research and development expenses increased to ¥60,905,616.89, a rise of 37.0% compared to ¥44,491,000.38 in the previous period[33] - Zhejiang WoWo Biotechnology invested RMB 43.45 million in Shanghai Kaiyi Pharmaceutical Technology Co., Ltd. to support its operational and long-term funding needs[19] - The registered capital of Kaiyi Pharmaceutical increased from RMB 260.107 million to RMB 316.615 million after the investment, with Zhejiang WoWo's ownership rising from 19.905% to 35.021%[19] Other Financial Metrics - The weighted average return on net assets was 8.04%, a decrease of 1.04 percentage points compared to the previous year[5] - The company received government subsidies totaling ¥13,262,221.63 during the reporting period[8] - Deferred income increased to ¥25,035,133.36 from ¥20,630,680.00, indicating a growth of 21.7%[29] - The company reported a cash and cash equivalents balance of CNY 216,616,892.70 at the end of the period, down from CNY 191,638,285.30[44] - The company received CNY 560,000,000.00 from investment recoveries, significantly up from CNY 308,000,000.00[41] - The company paid CNY 170,589,965.13 to employees, an increase from CNY 117,772,149.72, indicating a focus on workforce investment[41] Reporting and Compliance - The report for the third quarter of 2021 was not audited, indicating a potential area for further scrutiny[55] - The company has implemented new leasing standards effective from January 1, 2021, impacting asset and liability recognition[54]

Revenue and Profitability - The company's operating revenue for the reporting period was CNY 347,604,830.93, representing a 33.99% increase compared to CNY 259,428,281.04 in the same period last year[38]. - The net profit attributable to shareholders was CNY 147,316,566.21, up 37.61% from CNY 107,055,199.74 year-on-year[38]. - The net profit after deducting non-recurring gains and losses was CNY 132,813,880.84, reflecting a 26.85% increase from CNY 104,702,220.64 in the previous year[38]. - The net cash flow from operating activities was CNY 141,509,362.09, which is a 16.68% increase compared to CNY 121,281,305.63 in the same period last year[38]. - The growth in revenue and net profit is primarily due to the low base from the impact of COVID-19 in the first half of 2020[59]. Product Development and Regulatory Approvals - The new product "Artemisia Flower Pollen Allergen Sublingual Drops" received regulatory approval on January 30, 2021, but large-scale sales will take time to develop[12]. - The company launched a new product, the "Artemisia Flower Pollen Sublingual Drops," which received approval from the National Medical Products Administration on January 30, 2021[50]. - The company has received approval for its sublingual allergen immunotherapy products, including "Dust Mite Drops" and "Artemisia Pollen Sublingual Drops," enhancing its product line and market competitiveness[66]. - The development of new drugs is subject to lengthy regulatory processes, which may delay market entry and affect competitiveness[15]. - The company acknowledges risks in new drug development due to stringent regulatory requirements, which can prolong the time from research to market[110]. Market Strategy and Risks - The company plans to strengthen the promotion of new products to accelerate their market entry and reduce reliance on existing products[12]. - The company aims to enhance hospital coverage and academic marketing to adapt to market changes and maintain revenue stability[10]. - The company is facing risks from price reductions in the pharmaceutical industry due to healthcare cost control measures[8]. - The company is experiencing a trend of price reductions in pharmaceuticals, which may impact sales in certain regions, prompting a potential strategy to maintain price stability by possibly forgoing sales in some areas[109]. - The company plans to enhance the promotion of existing products to mitigate external factors affecting sustainable growth[110]. Financial Position and Investments - The total assets at the end of the reporting period were CNY 1,672,994,248.84, an increase of 4.25% from CNY 1,604,755,527.30 at the end of the previous year[38]. - The net assets attributable to shareholders were CNY 1,519,448,460.30, up 4.36% from CNY 1,455,908,680.17 at the end of the previous year[38]. - The company received government subsidies amounting to CNY 12,726,412.52 during the reporting period[45]. - The company completed the acquisition of a stake in Shanghai Kaiyi Pharmaceutical Technology Co., increasing its ownership to 35.021%, making it an associate company[67]. - The company has invested CNY 285.96 million in the "Allergen Point Injection Liquid Technical Transformation Project" using raised funds[93]. Research and Development - The company has established a robust R&D team and a fully autonomous R&D chain to enhance its product development capabilities[57]. - Research and development investment totaled ¥44,805,794.93, accounting for 12.89% of operating income, with stem cell research receiving ¥22,053,934.57 and natural medicine research receiving ¥4,860,006.34[72]. - The company emphasizes continuous R&D and innovation to maintain its competitive edge in the pharmaceutical market[68]. - The company is actively expanding into the natural medicine sector, focusing on discovering new structures and molecules to combat antibiotic-resistant bacteria[62]. - The company is in the process of developing new antibiotics to address the urgent need for treatments against "superbugs," leveraging China's rich biological resources[62]. Environmental and Social Responsibility - The company has established environmental protection measures and complies with relevant laws, ensuring that pollution control facilities are operational[125]. - The company promotes a "green office" initiative, utilizing electronic document management to save paper and implementing energy-saving practices in the workplace[129]. - The company actively engages in social responsibility initiatives, including supporting impoverished students and families through charitable actions[132]. - The company has developed an emergency response plan for environmental incidents, enhancing its management of potential environmental risks[125]. - The company achieved energy management system certification in May 2021, effectively reducing energy consumption and improving energy efficiency[126]. Governance and Compliance - The company maintains a robust governance structure to protect shareholder rights, ensuring accurate and timely information disclosure[127]. - There were no instances of non-operating fund occupation by controlling shareholders or related parties during the reporting period[140]. - The company reported no violations regarding external guarantees during the reporting period[141]. - The company did not undergo an audit for the semi-annual financial report[142]. - The company has no significant guarantees during the reporting period[162].

Financial Performance - The company's revenue for Q1 2021 was CNY 164,654,385.39, representing a 49.31% increase compared to CNY 110,275,663.26 in the same period last year[8]. - Net profit attributable to shareholders was CNY 70,454,208.66, a 70.31% increase from CNY 41,368,706.64 year-over-year[8]. - The company achieved operating revenue of CNY 164,654,385.39, an increase of 49.31% compared to the same period last year[26]. - The net profit attributable to shareholders reached CNY 70,454,208.66, reflecting a growth of 70.31% year-on-year[26]. - The company reported a total profit of ¥80,882,386.26 for the current period, up from ¥47,975,664.52 in the previous period, marking an increase of around 68.5%[81]. - The company reported a total comprehensive income of ¥67,728,189.15 for the current period, compared to ¥40,235,491.85 in the previous period, reflecting a growth of approximately 68.3%[84]. Cash Flow and Liquidity - The net cash flow from operating activities reached CNY 99,954,766.48, up 47.60% from CNY 67,719,778.94 in the previous year[8]. - Cash inflow from operating activities totaled ¥208,110,123.73, up from ¥160,933,608.23, reflecting a growth of approximately 29.3%[96]. - Cash and cash equivalents increased by CNY 100,408,803.99, a significant rise of 182.66% due to improved cash flow from operations and investments[25]. - Cash and cash equivalents at the end of the period were ¥376,413,028.97, up from ¥204,794,812.25, reflecting an increase of approximately 83.5%[98]. - The company experienced a net increase in cash and cash equivalents of ¥155,378,384.69, compared to ¥54,969,580.70 in the previous period, showing strong liquidity growth[98]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,690,191,869.39, reflecting a 5.32% increase from CNY 1,604,755,527.30 at the end of the previous year[8]. - Current liabilities rose to CNY 64,949,417.92, compared to CNY 55,419,690.55, indicating an increase of approximately 17.36%[63]. - Total liabilities reached CNY 94,315,851.61, up from CNY 76,607,698.67, marking a growth of around 23.14%[63]. - Owner's equity increased to CNY 1,595,876,017.78 from CNY 1,528,147,828.63, showing a growth of about 4.42%[66]. - Non-current assets totaled CNY 456,869,820.84, an increase from CNY 433,817,332.64, reflecting a growth of about 5.73%[66]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 23,588[12]. - The largest shareholder, Zhejiang Wowo Management Consulting Co., Ltd., held 38.86% of the shares[13]. Research and Development - Research and development expenses rose by CNY 9,229,096.19, an increase of 84.50%, driven by enhanced investment in stem cell and natural medicine research[24]. - The newly developed product, "Artemisia Annua Pollen Allergen Sublingual Drops," received regulatory approval on January 30, 2021, but large-scale sales will take time, highlighting ongoing reliance on existing products[34]. - The company plans to enhance the promotion of "Artemisia Annua Pollen Allergen Sublingual Drops" to expedite its market entry and reduce reliance on existing products[34]. Government Subsidies and Other Income - The company received government subsidies amounting to CNY 10,083,635.66 during the reporting period[8]. - The company received government subsidies related to daily operations, resulting in other income increasing by CNY 10,200,362.77, a staggering growth of 568,632.81%[24]. Risks and Challenges - The company faces risks related to industry policy changes and potential price reductions in drug tenders, which may impact future performance[29]. - The company faces risks in new drug development due to stringent regulatory requirements, which can delay market entry and affect competitiveness if clinical trials do not meet expectations[35]. - The company has faced challenges in ensuring new drugs gain market acceptance, which could impact sales volume if they lack competitiveness[35]. Investment and Projects - The company has received approval from the China Securities Regulatory Commission for a specific stock issuance to fund projects, including a natural medicine utilization base and an animal testing center[36]. - The company terminated the "Marketing Network Expansion and Information Technology Construction Project" and will permanently supplement the remaining raised funds of CNY 2,888.52 million into working capital[48]. - The "Annual Production of 3 Million Dust Mite Drops Technology Renovation Project" has an actual investment of CNY 11,427.52 million, achieving 97.92% of the planned investment[45]. - The "Allergen Research and Development Center Technology Renovation Project" has an actual investment of CNY 4,429.32 million, achieving 94.95% of the planned investment[45].